A Phase III Trial to Test the Efficacy of ZD4054, an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.
Latest Information Update: 06 Apr 2022
At a glance
- Drugs Zibotentan (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms ENTHUSE-M1
- Sponsors AstraZeneca
- 11 Jul 2012 Results published in Cancer.
- 11 Oct 2011 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
- 11 Oct 2011 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.